Cellarity Recognized as a 2023 Prix Galien USA Nominee for Best Startup

Widely considered the industry’s highest accolade for pharmaceutical research and development, the Prix Galien rewards innovative treatments and technologies that improve human health

SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Cellarity a 2023 Prix Galien USA Award nominee for “Best Startup.” Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2023, at the American Museum of Natural History in New York City.

Cellarity’s single-cell AI platform is an entirely new approach to drug discovery. Cellarity uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. By embracing the complexity of disease biology, instead of starting from a single target, the Cellarity platform uncovers novel actionable biological insights to create medicines that were previously out of reach.

“Cellarity is opening new possibilities to unlock treatments for a vast array of diseases,” said Fabrice Chouraqui, Pharm.D., CEO of Cellarity and CEO-Partner at Flagship Pioneering. “As the medicines we create are aimed at addressing the cellular dysfunction underlying the disease process, our platform is designed to drive much higher clinical success.”

“The Prix Galien Awards Committee is delighted to celebrate this remarkable group of candidates and selecting this year’s winners will be no easy feat,” said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Medical Technology, Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. “This great list of nominees reflects the undeniable courage, dedication, and passion behind each researcher continually working to deliver answers to patients around the world. We applaud their efforts and look forward to celebrating our shared goal of improving the human condition.”

About the Galien Foundation

The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit www.galienfoundation.org.

About Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. For further information, visit www.businessfrance.fr.

About Cellarity

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology. For more information, visit www.cellarity.com.

Contacts

Jessica Yingling, Ph.D., press@cellarity.com